AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common ...

Wave Life Sciences (NASDAQ:WVE) highlighted upcoming clinical catalysts across its obesity and RNA editing programs during a ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute ...

A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute for Brain Development has ...

Korro Bio's RNA editing platform, OPERA, targets genetic diseases by performing precise, transient single-base edits on RNA, reducing the risks associated with DNA editing. Lead asset KRRO-110 aims to ...

ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR) ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they transcribe into RNA help determine which type of neuron ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...

Early overactivity of ADARB1 accelerates RNA editing in developing brain regions, affecting gene function, neuronal ...